Could an early shot stop asthma in its tracks?
NCT ID NCT07309614
Summary
This study is testing whether giving the medication dupilumab earlier to people with moderate, high-risk asthma can help them achieve complete control, called remission, before their condition becomes severe. It will compare dupilumab injections to a placebo in 150 adults over one year to see if early treatment prevents asthma attacks and lung damage better than current standard care. The goal is to shift asthma treatment from reacting to severe symptoms to proactively preventing them.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA CONTROL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CIUSSS de l'Estrie- CHUS
RECRUITINGSherbrooke, Quebec, J1H 5H6, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Institut universitaire de cardiologie et de pneumologie de Québec
NOT_YET_RECRUITINGQuébec, Quebec, G1V 4G5, Canada
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
McGill University Health Centre
NOT_YET_RECRUITINGMontreal, Quebec, H4A 3S5, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Oxford University Hospitals NHS Foundation Trust - John Radcliffe Hospital
NOT_YET_RECRUITINGOxford, Oxfordshire, OX3 9DU, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Sir Charles Gairdner Hospital
NOT_YET_RECRUITINGNedlands, Western Australia, 6009, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.